免疫检查点抑制剂在肿瘤治疗中的研究进展

Progress on Immune Checkpoint Inhibitors in Tumor Therapy

免疫疗法为肿瘤治疗提供了新的途径,具有独特的优势和巨大的潜力,而免疫检查点阻断是免疫治疗中的重要组成部分。目前免疫检查点阻断在临床上已取得了重要进展,国内外许多企业已研发出靶向免疫检查点的抗体,并在特定适应症中取得了良好的临床效果。详细阐述了免疫检查点中细胞毒性T淋巴细胞相关抗原4(cytotoxic T lymphocyte associated antigen 4,CTLA-4)、程序性死亡受体(programmed death 1,PD-1)及其配体(programmed death ligand 1,PD-L1)的作用机制和国内外企业对其抗体药物的研发现状,并对其他免疫检查点的研究进展也做了一定的介绍,以期为免疫治疗的相关研究提供新思路。

Immunotherapy which has unique advantages and great potential provides a new approach for the treatment of tumor, and immune checkpoints blocking is an important part of immunotherapy. At present, the blockade of immune checkpoints has made important progress in clinical research. Many domestic and foreign enterprises have developed antibodies targeting immune checkpoints and achieved good clinical effects on specific indications. The action mechanism of cytotoxic T lymphocyte associate protein 4(CTLA-4), programmed death-1(PD-1) and its ligand(PD-L1) of immune checkpoints as well as the development status of their antibody drugs in domestic and foreign enterprises were expounded in detail, and the progress on other immune checkpoints was also summarized, in order to provide new ideas for the research of immunotherapy.